Rosiglitazone and cardiovascular disease: an epidemiologist's perspective

Abstract

References

1. Nissen SE , Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71.

2. Psaty BM , Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;356:2522–4.

3. Gerstein HC , Yusuf S , Bosch J. et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–105.

4. Kahn SE , Haffner SM , Heise MA. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–43.

5. Home PD , Pocock SJ , Beck-Nielsen H et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005;48:1726–35.

6. Brooks MM , Frye RL , Genuth S. et al. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006;97:9G–19G.

7. Action to Control Cardiovascular Risk in Diabetes (ACCORD): http://www.accordtrial.org/public/index.cfm

8. Dormandy JA , Charbonnel B , Eckland DJ. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–89.

9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65.

10.

10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.